Ashvattha Therapeutics is a drug company pursuing commercial applications of a novel dendrimer technology developed at Johns Hopkins that will create a suite of new pharmaceutical products for brain and ocular disorders.

The dendrimer opens new therapeutic avenues in a broad range of applications due to its ability to selectively target drugs to specific cell types. Ashvattha’s commercialization strategy relies on the creation of subsidiaries that will sublicense the dendrimer technology for particular medical indications.